Caplin Point Laboratories, through its subsidiaries, has acquired 10 approved Abbreviated New Drug Applications (ANDAs) for injectable and ophthalmic products. These ANDAs were acquired from a leading multinational generic product manufacturer. The addressable market for these products was $473.2 million for the 12-month period ending in August 2025. This acquisition strengthens Caplin Point’s U.S. market presence.
Acquisition Overview
Caplin Point Laboratories Limited has expanded its product portfolio through the acquisition of 10 approved ANDAs for both injectable and ophthalmic products. This acquisition was completed via its subsidiary companies, Caplin Steriles Limited (CSL) and Caplin One Labs Limited (COL). The acquired ANDAs will enhance the company’s offerings in the U.S. market.
Strategic Rationale
The company plans to leverage this acquisition to bolster its market position in the United States. Mr. C.C. Paarthipan, Chairman, stated that the U.S. market remains a critical growth driver for Caplin Point. He also noted that the acquired portfolio includes select oncology injectables, which will be transferred to and commercialized from the company’s new dedicated oncology facility in Kakkalur. The company aims to extend these products to non-U.S. markets, including Mexico, Canada, the European Union, and Brazil.
Financial Details
The addressable market size for the acquired products is estimated at $473.2 million, based on the 12-month period ending August 2025. This acquisition is expected to contribute positively to the company’s revenue stream.
About Caplin Steriles and Caplin One Labs
Caplin Steriles Limited (CSL) has developed and filed 53 ANDAs in the USA, with 49 approvals so far. CSL is also working on a portfolio of 55+ simple and complex injectable and ophthalmic products with plans to file them over the next 4 years. Caplin One Labs Limited (COL) is in its second year of operations at its oncology unit in Kakkalur. COL has acquired 5 out of the 10 ANDAs covered under the current acquisition.
Source: BSE
